| Literature DB >> 34489503 |
Carolina Reis1, Beatriz S Arruda1, Alek Pogosyan1, Peter Brown1, Hayriye Cagnan2.
Abstract
Essential tremor is a common neurological disorder, characterised by involuntary shaking of a limb. Patients are usually treated using medications which have limited effects on tremor and may cause side-effects. Surgical therapies are effective in reducing essential tremor, however, the invasive nature of these therapies together with the high cost, greatly limit the number of patients benefiting from them. Non-invasive therapies have gained increasing traction to meet this clinical need. Here, we test a non-invasive and closed-loop electrical stimulation paradigm which tracks peripheral tremor and targets thalamic afferents to modulate the central oscillators underlying tremor. To this end, 9 patients had electrical stimulation delivered to the median nerve locked to different phases of tremor. Peripheral stimulation induced a subtle but significant modulation in five out of nine patients-this modulation consisted mainly of amplification rather than suppression of tremor amplitude. Modulatory effects of stimulation were more pronounced when patient's tremor was spontaneously weaker at stimulation onset, when significant modulation became more frequent amongst subjects. This data suggests that for selected individuals, a more sophisticated control policy entailing an online estimate of both tremor phase and amplitude, should be considered in further explorations of the treatment potential of tremor phase-locked peripheral stimulation.Entities:
Mesh:
Year: 2021 PMID: 34489503 PMCID: PMC8421420 DOI: 10.1038/s41598-021-96660-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Patient-specific changes in tremor severity during phase-specific stimulation. The median change in tremor severity at the dominant (tracked) axis while stimulating at different phases of the tremor cycle (0°–330°), is shown by the stem plots in dark blue (amplitude response curves, ARCs). Change in tremor severity has been normalised so that 0 denotes no modulation of tremor severity, − 1 indicates complete tremor suppression and positive values indicate tremor amplification. The shaded light blue area represents the 25th and 75th percentile of change in tremor severity (across phase specific stimulation trials). Red dots indicate phases at which stimulation induced modulation of tremor is beyond natural variability of tremor. Note that half of the cohort has at least one stimulation phase where effects were significant and that only patient 9 shows statistically significant bi-directional (i.e., amplification and suppression) stimulation effects.
Figure 2Group analysis of tremor modulation with peripheral stimulation. Maximum amplification (a) and suppression (b) of tremor amplitude across patients during phase-specific stimulation (red bars) and no-stimulation (grey bars) have been statistically compared using a Wilcoxon signed rank test (tremor amplification p = 0.702 and tremor suppression p = 0.129). Black dots indicate individual maximum changes in tremor severity and bars their median.
Figure 3Individual stimulation effects during low and high tremor amplitude. (a) Shows individual amplitude response curves after dividing the data according to the tremor amplitude during the second prior to stimulation onset. Data are shown for the dominant (tracked) axis. Light blue bars corresponding to ARCs computed from stimulation blocks where tremor amplitude prior to stimulation was below the median tremor amplitude across the stimulation condition and dark blue bars where tremor amplitude prior to stimulation was above the median. Red dots indicate the phases at which stimulation induced a change in tremor severity significantly different to that observed naturally during similarly analysed unstimulated data. (b) Indicates that the mean absolute effect size obtained by peripheral stimulation when delivered at spontaneously low tremor amplitude epochs (light blue) is significantly higher than when delivered at high tremor amplitude epochs (dark blue) (p = 0.012).
Clinical information and stimulation parameters of patients included in the study.
| Case | Age, sex | Age at onset | ET family history | Tremor reduction w/alcohol | Tremor amplitude (m/s2) | Medication | Stim intensity (mA) | Tolerable stimulation |
|---|---|---|---|---|---|---|---|---|
| 1 | 65M | 60 | N | Y | 4.97 ± 1.37 | Propranolol | 8 | Strongly agree |
| 2 | 67M | 52 | N | NA | 3.39 ± 0.76 | Primidone | 9 | Strongly agree |
| 3 | 71M | < 20 | Y | Y | 10.65 ± 0.92 | N | 11 | Strongly agree |
| 4 | 67F | 14 | Y | Y | 1.81 ± 0.52 | Propranolol Gabapentin | 9 | – |
| 5 | 72M | 69 | N | Y | 6.78 ± 0.57 | N | – | Strongly agree |
| 6 | 84F | 56 | N | Y | 5.90 ± 0.43 | Propranolol | 6 | Agree |
| 7 | 73M | 7 | Y | Y | 11.08 ± 4.72 | N | 16 | Agree |
| 8 | 71M | 65 | Y | Y | 1.91 ± 0.55 | Propranolol | 10 | Strongly agree |
| 9 | 64M | < 15 | Y | Y | 2.02 ± 0.18 | N | 7 | Strongly agree |
Age and age at onset are in years. M = male; F = female; N = no; Y = yes; NA = not applicable as teetotal; – = missing observation. Tremor amplitude reflects the mean ± std tremor acceleration during the non-stimulation condition.